These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28105566)

  • 1. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
    Jimeno A; Sharma MR; Szyldergemajn S; Gore L; Geary D; Diamond JR; Fernandez Teruel C; Soto Matos-Pita A; Iglesias JL; Cullell-Young M; Ratain MJ
    Invest New Drugs; 2017 Aug; 35(4):471-477. PubMed ID: 28105566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors.
    Elez ME; Tabernero J; Geary D; Macarulla T; Kang SP; Kahatt C; Pita AS; Teruel CF; Siguero M; Cullell-Young M; Szyldergemajn S; Ratain MJ
    Clin Cancer Res; 2014 Apr; 20(8):2205-14. PubMed ID: 24563480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors.
    Metaxas Y; Kahatt C; Alfaro V; Fudio S; Zeaiter A; Plummer R; Sessa C; Von Moos R; Forster M; Stathis A
    Invest New Drugs; 2022 Feb; 40(1):91-98. PubMed ID: 34453241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors.
    Paz-Ares L; Forster M; Boni V; Szyldergemajn S; Corral J; Turnbull S; Cubillo A; Teruel CF; Calderero IL; Siguero M; Bohan P; Calvo E
    Invest New Drugs; 2017 Apr; 35(2):198-206. PubMed ID: 27873130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Benton CB; Chien KS; Tefferi A; Rodriguez J; Ravandi F; Daver N; Jabbour E; Jain N; Alvarado Y; Kwari M; Pierce S; Maiti A; Hornbaker M; Santos MA; Martinez S; Siguero M; Zblewski D; Al-Kali A; Hogan WJ; Kantarjian H; Pardanani A; Garcia-Manero G
    Hematol Oncol; 2019 Feb; 37(1):96-102. PubMed ID: 30153704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors.
    Poveda A; Oaknin A; Romero I; Guerrero-Zotano A; Fariñas-Madrid L; Rodriguez-Freixinos V; Mallol P; Lopez-Reig R; Lopez-Guerrero JA
    Sci Rep; 2021 Feb; 11(1):4433. PubMed ID: 33627685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetic-Pharmacodynamic Modeling and Covariate Analyses of Neutropenia and Thrombocytopenia in Patients With Solid Tumors Treated With Lurbinectedin.
    Fernández-Teruel C; Lubomirov R; Fudio S
    J Clin Pharmacol; 2021 Sep; 61(9):1206-1219. PubMed ID: 33914350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma.
    Cote GM; Haddox CL; Choy E; Merriam PA; Mazzola E; Venkataraman V; Alcindor T; Wagner AJ; Demetri GD; George S
    Clin Cancer Res; 2024 Jul; 30(13):2702-2708. PubMed ID: 38723278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study.
    Olmedo ME; Forster M; Moreno V; López-Criado MP; Braña I; Flynn M; Doger B; de Miguel M; López-Vilariño JA; Núñez R; Kahatt C; Cullell-Young M; Zeaiter A; Calvo E
    Invest New Drugs; 2021 Oct; 39(5):1275-1283. PubMed ID: 33704620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
    Cruz C; Llop-Guevara A; Garber JE; Arun BK; Pérez Fidalgo JA; Lluch A; Telli ML; Fernández C; Kahatt C; Galmarini CM; Soto-Matos A; Alfaro V; Pérez de la Haza A; Domchek SM; Antolin S; Vahdat L; Tung NM; Lopez R; Arribas J; Vivancos A; Baselga J; Serra V; Balmaña J; Isakoff SJ
    J Clin Oncol; 2018 Nov; 36(31):3134-3143. PubMed ID: 30240327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical and pharmacokinetic study of BBR 3576, a novel aza-anthrapyrazole, administered i.v. every 4 weeks in patients with advanced solid tumors: a phase I study group trial of the Central European Society of Anticancer-Drug Research (CESAR).
    Mross K; Scheulen ME; Licht T; Unger C; Richly H; Stern AC; Kutz K; Camboni MG; Barbieri P; Verdi E; Vincenzi B; Bernareggi A
    Anticancer Drugs; 2004 Jan; 15(1):15-22. PubMed ID: 15090738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.
    Fudio S; Tabernero J; Subbiah V; Chawla SP; Moreno V; Longo F; Lopez R; Anton A; Trigo JM; Shapiro G; Jeong W; Villalobos VM; Lubomirov R; Fernandez-Teruel C; Alfaro V; Boni V
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):113-124. PubMed ID: 33108504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
    Cote GM; Choy E; Chen T; Marino-Enriquez A; Morgan J; Merriam P; Thornton K; Wagner AJ; Nathenson MJ; Demetri G; George S
    Eur J Cancer; 2020 Feb; 126():21-32. PubMed ID: 31896519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-Pharmacokinetic and Covariate Analysis of Lurbinectedin (PM01183), a New RNA Polymerase II Inhibitor, in Pooled Phase I/II Trials in Patients with Cancer.
    Fernandez-Teruel C; Gonzalez I; Trocóniz IF; Lubomirov R; Soto A; Fudio S
    Clin Pharmacokinet; 2019 Mar; 58(3):363-374. PubMed ID: 30090974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study.
    Calvo E; Moreno V; Flynn M; Holgado E; Olmedo ME; Lopez Criado MP; Kahatt C; Lopez-Vilariño JA; Siguero M; Fernandez-Teruel C; Cullell-Young M; Soto Matos-Pita A; Forster M
    Ann Oncol; 2017 Oct; 28(10):2559-2566. PubMed ID: 28961837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
    Trigo J; Subbiah V; Besse B; Moreno V; López R; Sala MA; Peters S; Ponce S; Fernández C; Alfaro V; Gómez J; Kahatt C; Zeaiter A; Zaman K; Boni V; Arrondeau J; Martínez M; Delord JP; Awada A; Kristeleit R; Olmedo ME; Wannesson L; Valdivia J; Rubio MJ; Anton A; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D'Arcangelo M; Santoro A; Villalobos VM; Sands J; Paz-Ares L
    Lancet Oncol; 2020 May; 21(5):645-654. PubMed ID: 32224306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study.
    Kristeleit R; Moreno V; Boni V; Guerra EM; Kahatt C; Romero I; Calvo E; Basté N; López-Vilariño JA; Siguero M; Alfaro V; Zeaiter A; Forster M
    Int J Gynecol Cancer; 2021 Nov; 31(11):1428-1436. PubMed ID: 34610971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate.
    Meyer H; Sunkara R; Rothmann E; Shah A; Riaz I; Courtney KD; Armstrong AJ; Lippucci A; Naqvi SAA; Stanton ML; Beltran H; Bryce AH
    Clin Genitourin Cancer; 2024 Oct; 22(5):102172. PubMed ID: 39232269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors.
    Capdevila J; Clive S; Casado E; Michie C; Piera A; Sicart E; Carreras MJ; Coronado C; Kahatt C; Soto Matos-Pita A; Fernandez Teruel C; Siguero M; Cullell-Young M; Tabernero J
    Cancer Chemother Pharmacol; 2013 May; 71(5):1247-54. PubMed ID: 23455428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
    Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.